SSA
IOVA icon

Schonfeld Strategic Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1K Buy
+14,921
New +$56.7K ﹤0.01% 2358
2025
Q1 		– Sell
-64,850
Closed -$480K – 2341
2024
Q4 		$480K Sell
64,850
-330,597
-84% -$3.06M ﹤0.01% 1425
2024
Q3 		$3.71M Buy
+395,447
New +$3.75M 0.02% 640
2024
Q2 		– Sell
-244,447
Closed -$3.62M – 2346
2024
Q1 		$3.62M Sell
244,447
-777,371
-76% -$9.05M 0.02% 761
2023
Q4 		$8.31M Buy
+1,021,818
New +$5.35M 0.06% 406
2023
Q3 		– Sell
-36,751
Closed -$259K – 2007
2023
Q2 		$259K Sell
36,751
-265,767
-88% -$1.9M ﹤0.01% 1447
2023
Q1 		$1.85M Sell
302,518
-695,582
-70% -$4.8M 0.02% 710
2022
Q4 		$6.38M Buy
998,100
+824,917
+476% +$6.44M 0.05% 413
2022
Q3 		$1.66M Buy
+173,183
New +$2M 0.01% 969
2021
Q4 		– Sell
-91,641
Closed -$2.26M – 2329
2021
Q3 		$2.26M Buy
91,641
+82,441
+896% +$1.94M 0.02% 678
2021
Q2 		$239K Sell
9,200
-20,301
-69% -$528K ﹤0.01% 1586
2021
Q1 		$935K Buy
29,501
+21,169
+254% +$877K 0.01% 923
2020
Q4 		$387K Sell
8,332
-42,637
-84% -$1.69M 0.01% 1118
2020
Q3 		$1.68M Buy
50,969
+7,610
+18% +$233K 0.03% 560
2020
Q2 		$1.19M Buy
43,359
+31,224
+257% +$1.03M 0.03% 563
2020
Q1 		$363K Sell
12,135
-214,716
-95% -$5.69M 0.02% 683
2019
Q4 		$6.28M Buy
226,851
+84,251
+59% +$1.92M 0.15% 163
2019
Q3 		$2.6M Buy
142,600
+122,800
+620% +$2.72M 0.08% 268
2019
Q2 		$485K Sell
19,800
-168,630
-89% -$2.54M 0.02% 639
2019
Q1 		$1.79M Sell
188,430
-749,870
-80% -$7.28M 0.06% 370
2018
Q4 		$8.3M Buy
+938,300
New +$9.05M 0.32% 74
2018
Q2 		– Sell
-29,541
Closed -$499K – 848
2018
Q1 		$499K Buy
+29,541
New +$447K 0.04% 477
2017
Q3 		– Sell
-34,024
Closed -$250K – 680
2017
Q2 		$250K Buy
+34,024
New +$216K 0.03% 518

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Schonfeld Strategic Advisors's IOVA Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 14,921 shares worth $62.1K. The stake represents ﹤0.01% of the portfolio and ranks #2358 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in IOVA as recently as Q4 2024.

Schonfeld Strategic Advisors first reported a position in IOVA in Q2 2017 and has held it in 23 quarters since. The position peaked at $8.31M in Q4 2023. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Schonfeld Strategic Advisors held 14,921 shares of Iovance Biotherapeutics worth $62.1K as of Q2 2026.
  • Iovance Biotherapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2358 holding.
  • Schonfeld Strategic Advisors first reported a position in Iovance Biotherapeutics in Q2 2017 and has held it in 23 quarters since.
  • Schonfeld Strategic Advisors's Iovance Biotherapeutics position peaked at $8.31M in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.